Enhancing Protective Antibodies against Opioids through Antigen Display on Virus-like Particles

Area of Science:

• Immunology
• Pharmacology
• Vaccine Development

Background:

• Opioid use disorder (OUD) presents a significant public health challenge, marked by rising overdose fatalities.
• Vaccination strategies offer a promising complementary approach to combat OUD.
• Effective vaccines require the induction of high-affinity antibodies specific to the target drug.

Purpose of the Study:

• To evaluate the immunogenicity and efficacy of a novel vaccine conjugate, mQβ-6-AmHap, for combating opioid use disorder.
• To assess the potential of virus-like particle mutant bacteriophage Qβ (mQβ) as a carrier for small molecule haptens mimicking heroin.

Main Methods:

• Development of a conjugate using mQβ as a carrier for the heroin-mimicking hapten 6-AmHap.
• Immunization of mice with mQβ-6-AmHap and comparison with a tetanus toxoid-6-AmHap conjugate.
• Measurement of IgG antibody titers, antibody binding specificity, and assessment of vaccine effects on morphine-induced behaviors in mice.

Main Results:

• The mQβ-6-AmHap conjugate induced significantly higher IgG antibody levels against 6-AmHap compared to the tetanus toxoid conjugate.
• High anti-6-AmHap antibody titers persisted for at least 600 days post-immunization.
• Induced antibodies showed specific binding to heroin derivatives while minimally interacting with OUD medications.
• Vaccination effectively reduced morphine's impact on mouse ambulation and antinociception.

Conclusions:

• The mQβ-6-AmHap conjugate is a potent immunogen capable of eliciting persistent, specific antibodies against heroin and related compounds.
• This vaccine strategy demonstrates translational potential for mitigating the harmful effects of opioids and combating OUD.